SHINVA新华品牌怎么样 申请店铺

我要投票 SHINVA新华在医疗器械行业中的票数:61 更新时间:2024-12-23
SHINVA新华是哪个国家的品牌?「SHINVA新华」是 山东新华医疗器械股份有限公司 旗下著名品牌。该品牌发源于山东,由创始人许尚峰在1993期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
SHINVA新华怎么样

2002年9月,山东新华医疗器械股份有限公司在上海证券交易所上市,现为中国医疗器械行业协会会长单位。

山东新华医疗器械股份有限公司始终坚持拼搏诚信的齐鲁文化、以用户为中心的现代企业文化为企业核心价值观,用目标鼓舞士气,用发展凝聚人心,用创新提升素质,用文化打造实力,坚定不移地走健康产业之路,坚定不移地走技术创新之路,坚定不移地走资本运作之路,拥有医疗器械及装备、制药装备、医疗服务三大业务板块。

在医疗器械板块,已形成九大配置精良、技术完备的先进产品线,涵盖感染控制、放疗及影像、手术器械及骨科、手术室工程及设备、口腔设备及耗材、体外诊断试剂及仪器、生物材料及耗材、透析设备及耗材、医用环保及其他领域。

制药装备板块,由生物制药、特种输液、中药制剂、固体制剂四大工程技术中心组成,下设八个产品技术分厂和五个控股公司,集制药装备研发、制造及销售为一体。在常规制药装备生产之外,提供着“制药工艺、制药装备、制药工程”三位一体的优质服务;同时,为化学药、生物药、植物药工厂的建设提供整包服务,为客户解决一切后顾之忧。

在医疗服务领域,新华医疗持续提升着品牌竞争力和美誉度。凭借专业的投资、建设、运营及采购和服务平台,打造具有先进医疗理念、前沿科研水平、品牌经营连锁、资源有机融合的现代化医院集团。与此同时,新华医疗也在积极拓展着肾脏健康服务,利用公司专业化、集约化、连锁化的运营优势,为医院提供新技术、新管理、新模式,创建出一系列特色鲜明的肾脏病专科医院和血液透析中心,用无限的责任感和专业度,服务于广大肾病患者。未来,新华医疗,将以集团化、专业化、规范化的全新面貌,为更多患者提供完善医疗服务,成就发展健康产业之路的宏伟梦想。

公司以山东核心区域为研发、制造、营销和管理总部,同时有北京核心区域、上海核心区域。

心系健康,诚信天下。站在新的历史起点上,面对新的发展机遇,新华医疗将一如既往,与时俱进,以自信、创新和拼搏,去勇敢面对困难和挑战,为人类健康事业、为铸造中国医疗器械产业的丰碑、打造世界知名医疗器械生产企业而继续努力奋斗!

In September 2002, Shandong Xinhua medical device Co., Ltd. was listed on the Shanghai Stock Exchange and is now the chairman of China Medical Device Industry Association. Shandong Xinhua Medical Equipment Co., Ltd. always adheres to the Qilu culture of striving for integrity, the modern enterprise culture centered on users as the core values of the enterprise, encourages morale with goals, rallies people with development, improves quality with innovation, builds strength with culture, firmly takes the road of health industry, firmly takes the road of technological innovation, and firmly takes the road of capital The way of operation, with medical devices and equipment, pharmaceutical equipment, medical services three business sectors. In the medical equipment sector, nine advanced product lines with excellent configuration and complete technology have been formed, covering infection control, radiotherapy and imaging, surgical equipment and orthopedics, operating room engineering and equipment, oral equipment and consumables, in vitro diagnostic reagents and instruments, biomaterials and consumables, dialysis equipment and consumables, medical environmental protection and other fields. The pharmaceutical equipment sector is composed of four engineering technology centers, including biopharmaceutical, special infusion, traditional Chinese medicine preparation and solid preparation. It has eight product technology branches and five holding companies, integrating the R & D, manufacturing and sales of pharmaceutical equipment. In addition to the production of conventional pharmaceutical equipment, it provides the high-quality service of "pharmaceutical technology, pharmaceutical equipment, pharmaceutical engineering"; at the same time, it provides the whole package service for the construction of chemical medicine, biological medicine, plant medicine factories, and solves all the worries for customers. In the field of medical services, Xinhua medical continues to enhance its brand competitiveness and reputation. With professional investment, construction, operation, procurement and service platform, we will build a modern hospital group with advanced medical concept, cutting-edge scientific research level, brand management chain and organic integration of resources. At the same time, Xinhua medical is also actively expanding kidney health services, taking advantage of the company's professional, intensive and chain operation advantages to provide new technology, new management and new mode for the hospital, creating a series of distinctive kidney disease specialized hospitals and hemodialysis centers, serving the vast number of nephrotic patients with unlimited sense of responsibility and professionalism. In the future, Xinhua medical will take a new look of collectivization, specialization and standardization to provide more patients with perfect medical services and achieve the grand dream of developing health industry. The company takes the core area of Shandong Province as its R & D, manufacturing, marketing and management headquarters, and has the core areas of Beijing and Shanghai. Heart health, integrity world. Standing at a new historical starting point and facing new development opportunities, Xinhua medical will, as always, keep pace with the times, bravely face difficulties and challenges with self-confidence, innovation and hard work, and continue to strive for the cause of human health, the building of a monument of China's medical device industry and the building of a world-famous medical device manufacturer!

本文链接: https://brand.waitui.com/f0c49f885.html 联系电话:0533-3583393

千城特选小程序码

7×24h 快讯

蚂蚁数科Deepfake检测方案获金融科技创新应用案例

36氪获悉,近日,在中关村论坛系列活动第12届数字金融与科技金融大会上,蚂蚁数科的 Deepfake 检测方案入选大会“金融科技技术创新与应用案例”。据了解,在金融业务场景中,蚂蚁数科多组测试数据集上的 Deepfake 检测准确率达到了98%以上,并成功阻止了多起利用Deepfake技术进行的欺诈行为,保护了用户的资产安全。

2小时前

修正后数据显示,英国第三季度经济增长陷入停滞

英国国家统计局周一公布的修正后的数据显示,英国第三季度经济增长陷入停滞,这加剧了英国首相斯塔默(Keir Starmer)领政府所面临的经济困境。英国国家统计局上个月公布的初步估计显示,第三季度GDP增长0.1%,但该机构周一将这一数字向下修正至0%。英国国家统计局还将第二季度GDP增长数字从此前估计的0.5%下修至0.4%。(新浪财经)

2小时前

香港金管局:人民币跨境清算服务时间延长有助于香港发挥离岸人民币业务枢纽作用

香港金融管理局相关部门发言人12月23日表示,自2024年12月23日起,人民币跨境清算服务时间将延长至24小时。香港金融管理局欢迎香港人民币清算行中国银行(香港)的优化措施,这有助于香港人民币清算系统更好地为处于不同时区的银行及客户提供服务,使香港进一步发挥离岸人民币业务枢纽的作用,巩固香港在人民币国际化进程中的独特角色。(上证报)

2小时前

莎普爱思:立他司特滴眼液获得临床试验批准通知书

36氪获悉,莎普爱思公告,公司近日收到国家药监局核准签发的立他司特滴眼液《药物临床试验批准通知书》,公司拟于条件具备后开展临床试验。该药品适用于治疗干眼症(DED)的症状和体征。截至公告披露日,立他司特滴眼液项目累计研发投入约1463.40万元人民币。

2小时前

本田汽车和日产汽车宣布签署考虑整并的基本协议

36氪获悉,据报道,本田汽车和日产汽车宣布签署考虑整并的基本协议。

2小时前

本页详细列出关于尼德克NIDEK的品牌信息,含品牌所属公司介绍,尼德克NIDEK所处行业的品牌地位及优势。
咨询